Year |
Citation |
Score |
2020 |
Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu L, Saw RPM, et al. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32739408 DOI: 10.1016/J.Annonc.2020.07.016 |
0.312 |
|
2020 |
Roy M, Ma J, Sahin AA, Damodaran S, Tetzlaff MT, Curry JL, Ciurea AM, Ning J, Torres-Cabala CA, Ivan D, Aung PP, Ross MI, Gershenwald JE, Davies MA, Prieto VG, et al. Abstract P3-08-38: Primary cutaneous melanoma of the breast in women. A retrospective study of 82 patients Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-08-38 |
0.328 |
|
2019 |
Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. PMID 31398264 DOI: 10.1002/Cncr.32454 |
0.301 |
|
2019 |
Ma J, Stingo FC, Hobbs BP. Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. Biometrical Journal. Biometrische Zeitschrift. PMID 30786040 DOI: 10.1002/Bimj.201700323 |
0.301 |
|
2018 |
McKean MA, Oba J, Ma J, Haydu LE, Bassett RL, Woodman SE. Immune checkpoint inhibitor responses in KIT-mutated metastatic melanoma. Journal of Clinical Oncology. 36: 199-199. DOI: 10.1200/Jco.2018.36.5_Suppl.199 |
0.303 |
|
2017 |
Clifton K, Barrera AG, Ma J, Bassett RL, Litton JK, Arun B. Adjuvant or neoadjuvant chemotherapy in early stage triple negative breast cancer (TNBC) comparison of outcomes in both BRCA positive and BRCA negative patients. Journal of Clinical Oncology. 35: 576-576. DOI: 10.1200/Jco.2017.35.15_Suppl.576 |
0.334 |
|
2016 |
Ma J, Hobbs BP, Stingo FC. Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Statistical Methods in Medical Research. PMID 27807177 DOI: 10.1177/0962280216675373 |
0.346 |
|
2016 |
Ma J, Chan W, Tilley BC. Continuous time Markov chain approaches for analyzing transtheoretical models of health behavioral change: A case study and comparison of model estimations. Statistical Methods in Medical Research. PMID 27048681 DOI: 10.1177/0962280216639859 |
0.479 |
|
2016 |
Ma J, Yu X, Symanski E, Doody R, Chan W. A Bayesian Approach in Estimating Transition Probabilities of a Discrete-time Markov Chain for Ignorable Intermittent Missing Data Communications in Statistics: Simulation and Computation. 45: 2598-2616. DOI: 10.1080/03610918.2014.911895 |
0.417 |
|
2015 |
Ma J, Stingo FC, Hobbs BP. Bayesian predictive modeling for genomic based personalized treatment selection. Biometrics. PMID 26575856 DOI: 10.1111/Biom.12448 |
0.306 |
|
2015 |
Ma J, Chan W, Tsai CL, Xiong M, Tilley BC. Analysis of transtheoretical model of health behavioral changes in a nutrition intervention study-a continuous time Markov chain model with Bayesian approach. Statistics in Medicine. PMID 26123093 DOI: 10.1002/Sim.6571 |
0.469 |
|
2004 |
Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, Selhub J, Hunter DJ, Ma J. Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. International Journal of Cancer. Journal International Du Cancer. 110: 617-20. PMID 15122597 DOI: 10.1002/Ijc.20148 |
0.384 |
|
2003 |
Chen J, Hunter DJ, Stampfer MJ, Kyte C, Chan W, Wetmur JG, Mosig R, Selhub J, Ma J. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 12: 958-62. PMID 14578129 |
0.392 |
|
Show low-probability matches. |